Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New drug: Carcinoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New drug:Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New drug:Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

New drug:Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Study:
  • Open-label, single-arm, phase II trial
  • Refractory to at least one line of systemic chemotherapy NPC
  • Camrelizumab + Apatinib q21 (n=58)
Efficacy:
  • ORR: 65% [51.9%-57.5%]
  • mPFS: 10.4 mos [7.2-3.6 mos]
Safety:
  • Grade 1-2: hypertension (51.7%), dysphagia (63.8%), pharyngolaryngeal pain (63.8%), hypothyroidism (53.4%)
  • Grade≥3 AEs: hypertension (19.0%), nasopharyngeal necrosis (10.3%), headache (12.1%).

JCO 2023; 03 FEB

Dingi Xi et al. ¨ Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study)¨

https://doi.org/10.1200/JCO.22.01450

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More